Natalizumab in relapsing-remitting multiple sclerosis

References

• Baron JL, Madri JA, Ruddle NH, et al. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parechyma. J Exp Med. 1993;177:57–68.
   PubMed Web of Science ®Google Scholar
• Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against 1 integrin. Nature. 1992;356:63–66.
   PubMed Web of Science ®Google Scholar
• Kent SJ, Karlik SJ, Cannon C, et al. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol. 1995;58:1–10.
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911–923.
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheramata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15–23.
   PubMed Web of Science ®Google Scholar
• Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59:743–747.
   PubMed Web of Science ®Google Scholar
• Sheremata WA, Vollmer TL, Stone LA, et al. A safety and pharmacokinetic study of intravenous natalizumab in patient with MS. Neurology. 1999;52:1072–1074.
   PubMed Web of Science ®Google Scholar
• Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK antergren study group. Neurology. 1999;53:466–472.
   PubMed Web of Science ®Google Scholar
• O’Connor PW, Goodman A, Willmer-Hulme AJ, et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. 2004;62:2038–2043.
   PubMed Web of Science ®Google Scholar
• Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol. 2004;251:407–413.
   PubMed Web of Science ®Google Scholar
• Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized double-blind placebo-controlled study. Neurology. 2009;72:806–812.
   PubMed Web of Science ®Google Scholar
• Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009;256:405–415.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological activity in multiple sclerosis: a retrospective analysis of the AFFIRM study. Lancet Neurol. 2009;8:254–260.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Miller D, Hass D, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007;62:219–228.
   PubMed Web of Science ®Google Scholar
• Isaksson AP, Ahlström G, Gunnarsson LG. Quality of life and impairment with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76:64–69.
   PubMed Web of Science ®Google Scholar
• Balcer LJ, Galetta SL, Polman CH, et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS. J Neurol Sci. 2012;318:119–124.
   PubMed Web of Science ®Google Scholar
• Voloshyna N, Havrdova E, Hutchinson M, et al. Natalizumab improves ambulation in relapsin-remitting multiples sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM. Eur J Neurol. 2015;22:570–577.
   PubMed Web of Science ®Google Scholar
• Trojano M. Poster O1217 EAN Berlin. Eur J Neurol. 2015;22(suppl1):49.
   Google Scholar
• Natalizumab SC. Similar to IV Every 4 Weeks for MS [Internet]. [cited 2016 Feb 10]. Available from: http://www.medscape.com/viewarticle/846795
   Google Scholar
• A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS) [Internet]. [cited 2016 Feb 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01416181
   Google Scholar
• Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler. 2015 Nov 19. pii: 1352458515616701. [Epub ahead of print].
   Google Scholar
• Enziger C, Fazekas F, Matthews PM, et al. Risk factors progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology. 2005;64:1704–1711.
   PubMed Web of Science ®Google Scholar
• Outteryck O, Ongagna JC, Zephir H, et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol. 2010;257:207–211.
   PubMed Web of Science ®Google Scholar
• Melin A, Outteryck O, Collongues N, et al. Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis. J Neurol. 2012;259:1215–1221.
   PubMed Web of Science ®Google Scholar
• Fernandez O, Oreja-Guevara C, Arroyo R, et al. Natalizumab treatment of multiple sclerosis in Spain: results of extensive observational study. J Neurol. 2012;259:1814–1823.
   PubMed Web of Science ®Google Scholar
• Prosperini L, Borrelio G, Fubelli F, et al. Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS centre in Rome. Neurol Sci. 2011;31:303–307.
   PubMed Web of Science ®Google Scholar
• Van Pesch V, Bartholomé E, Bissay V, et al. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program. Acta Neurol Belg. 2014;114:167–178.
   PubMed Web of Science ®Google Scholar
• Outteryck O, Ongagna JC, Brochet B, et al. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. Eur J Neurol. 2014;21:40–48.
   PubMed Web of Science ®Google Scholar
• Totaro R, Lugaresi A, Bellantonio P, et al. Natalizumab tretment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. Int J Immunopathol Pharmacol. 2014;27:147–154.
   PubMed Web of Science ®Google Scholar
• Huppke P, Stark W, Zürcher C, et al. Natalizumab use in pediatric multiple sclerosis. Arch Neurol. 2008;65:1655–1688.
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Pozzilli C, Grimaldi LM, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology. 2010;75:912–917.
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Pozzilli C, Grimaldi LM, et al. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler. 2013;19:1106–1112.
   PubMed Web of Science ®Google Scholar
• Arnal-Garcia C, Garcia-Monteiro MR, Malaga I, et al. Natalizumab use in pediatric patients with relapsin-remitting multiple sclerosis. Eur J Paediatr Neurol. 2013;17:50–54.
   PubMed Web of Science ®Google Scholar
• Kornek B, Aboul-Enein F, Rostasy K, et al. Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol. 2013;70:469–475.
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Moiola L, Pozzilli C, et al. Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol. 2015;15:174.
   PubMed Web of Science ®Google Scholar
• Ebrahimi N, Herbstritt S, Gold R, et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015;21:198–205.
   PubMed Web of Science ®Google Scholar
• Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71:891–895.
   PubMed Web of Science ®Google Scholar
• Ciron J, Hautecoeur P, Mathis S, et al. Natalizumab throughout pregnancy: risk of low platelet count in the newborn at delivery. Revue Neurol. 2016;172:165–166.
   PubMed Web of Science ®Google Scholar
• Portaccio E. ECTRIMS Barcelona 2015. Mult Scler. 2015;23(S11):34.
   Google Scholar
• Vukusic S, Durand-Dubief F, Benoit A, et al. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. Mult Scler. 2015;21:953–955.
   PubMed Web of Science ®Google Scholar
• Campbell JD, McQueen RB, Miravalle A, et al. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. Am J Manag Care. 2013;19:278–285.
   PubMed Web of Science ®Google Scholar
• Heisen M, Treur MJ, Van Der Hel WS, et al. Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in the Netherlands. J Med Econ. 2012;15:1149–1158.
   PubMedGoogle Scholar
• Bergvall N, Tambour M, Henrikssonn F, et al. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden. J Med Econ. 2013;16:349–357.
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Modeling the cost-effectiveness of new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult Scler. 2008;14:679–690.
   PubMed Web of Science ®Google Scholar
• Chiao E, Meyer K. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. Curr Med Res Opin. 2009;25:1445–1454.
   PubMed Web of Science ®Google Scholar
• Zhovtis-Ryerson L Presentation Session S57. ECTRIMS; 2015; Barcelona.
   Google Scholar
• Sorensen PS, Koch-Henriksen N, Jensen PE, et al. Neutralizing antibodies against interferon beta do not predispose antibodies against natalizumab? Neurology. 2011;76:759–760.
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Giovannoni G, Confaverux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69:1391–1403.
   PubMed Web of Science ®Google Scholar
• O’Connor PW, Goodman A, Kappos L, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study. Neurology. 2014;83:78–86.
   PubMed Web of Science ®Google Scholar
• Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol. 2010;68:392–395.
   PubMed Web of Science ®Google Scholar
• West TM, Cree BA. Natalizumab dosage suspension: are we helping or hurting ? Ann Neurol. 2010;68:395–399.
   PubMed Web of Science ®Google Scholar
• Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011;68:186–191.
   PubMedGoogle Scholar
• Sorensen PS, Koch-Henriksen N, Petersen T, et al. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol. 2014;261:1170–1177.
   PubMed Web of Science ®Google Scholar
• Kaufman M, Cree BA, De Sèze J, et al. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol. 2015;262:326–336.
   PubMed Web of Science ®Google Scholar
• O’Connor PW, Goodman A, Kappos L, et al. Disease activity during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76:1858–1865.
   PubMed Web of Science ®Google Scholar
• Stüve O, Cravens PD, Frohman EM, et al. Immunologic, clinical and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009;72:396–401.
   PubMed Web of Science ®Google Scholar
• Biogen, Inc. TYSABRI update. Cambridge (MA): Biogen, Inc; 2015.
   Google Scholar
• Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9:425–437.
   PubMed Web of Science ®Google Scholar
• Schippling S, Kempf C, Büchele F, et al. JC virus granule neuronopathy and GCN-IRIS under natalizumab treatment. Ann Neurol. 2013;74:622–626.
   PubMed Web of Science ®Google Scholar
• Berger R, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80:1430–1438.
   PubMed Web of Science ®Google Scholar
• Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9:438–436.
   PubMed Web of Science ®Google Scholar
• Wattjes MP, Vennegor A, Mostert J, et al. Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place? J Neurol. 2014;261:1139–1143.
   PubMed Web of Science ®Google Scholar
• Dong-Si T, Richman S, Wattjes MP, et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Neurol Transl Neurol. 2014;1:755–764.
   PubMed Web of Science ®Google Scholar
• Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011;76:1697–1704.
   PubMed Web of Science ®Google Scholar
• Dong-Si T, Gheuens S, Gangadharan A, et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurovirol. 2015;21:637–644.
   PubMed Web of Science ®Google Scholar
• Khule J, Gosert R, Bühler R, et al. Management and outcome of CSF-JC virus PCR negative PML in a natalizumab-treated patient with MS. Neurology. 2011;77:2010–2016.
   PubMed Web of Science ®Google Scholar
• Warnke C, von Geldern G, Markwerth P, et al. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76:792–801.
   PubMed Web of Science ®Google Scholar
• Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012;72:779–787.
   PubMed Web of Science ®Google Scholar
• Wattjes MP, Vennegor A, Steenwijk MD, et al. MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatry. 2015;86:793–798.
   PubMed Web of Science ®Google Scholar
• Wattjes MP, Richert ND, Killestein J, et al. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2013;19:1826–1840.
   PubMed Web of Science ®Google Scholar
• Hodel J, Darchis C, Outteryck O, et al. Punctate pattern. A promising imaging marker for the diagnosis of natalizumab-associated PML. Neurology. 2016 Mar 23. pii: 10.1212/WML.0000000000002586. [Epub ahead of print].
   PubMedGoogle Scholar
• Hodel J, Outteryck O, Dubron C, et al. Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab: diagnostic precision with MR imaging. Radiology. 2016;278:863–872.
   Google Scholar
• Miyagawa M, Maeda M, Umimo M, et al. Low signal intensity in U-fiber identified by susceptibility-weighted imaging in two cases of progressive multifocal leukoencephalopathy. J Neurol Sci. 2014;344:198–202.
   PubMed Web of Science ®Google Scholar
• Hodel J, Outteryck O, Verclytte S, et al. Brain magnetic susceptibility changes in patients with natalizumab-associated progressive multifocal leukoencephalopathy. Am J Neuroradiol. 2015;36:2296–2302.
   Web of Science ®Google Scholar
• Carra-Dalliere C, Menjot De Champfleur N, Deverdun J, et al. Use of quantitative susceptibility mapping (QSM) in progressive multifocal leukoencephalopathy. J Neuroradiol. 2016;43:6–10.
   PubMed Web of Science ®Google Scholar
• Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011;10:745–758.
   PubMed Web of Science ®Google Scholar
• Phan-Ba R, Lommers E, Moonen G, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2012;78:73.
   PubMedGoogle Scholar
• European Medical Agency on 12th February 2016. EMA/85655/2016. Updated recommendations to minimise the risk of the rare brain infecion PML with Tysabri. New advice may help early detection of PML and improve patients’ outcomes. Available on http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2016/02/WC500201891.pdf80.
   Google Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–1880.
   PubMed Web of Science ®Google Scholar
• Lee P, Plavina T, Castro A, et al. A second-generation ELISA for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol. 2013;57:141–146.
   PubMed Web of Science ®Google Scholar
• Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76:802–812.
   PubMed Web of Science ®Google Scholar
• McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016;87:117–125.
   PubMed Web of Science ®Google Scholar
• Vennegoor A, Van Rossum JA, Polman CH, et al. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progresive multifocal leukoencephalopathy. Mult Scler. 2015;21:1600–1603.
   PubMed Web of Science ®Google Scholar
• Villar LM, Costa-Frossart L, Masterman T, et al. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy. Ann Neurol. 2015;77:447–457.
   PubMed Web of Science ®Google Scholar
• Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-selectine is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013;81:865–871.
   PubMed Web of Science ®Google Scholar
• Spadaro M, Caldano M, Marnetto F, et al. Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. J Neuroinflammation. 2015;12:146.
   PubMed Web of Science ®Google Scholar
• Schwab N, Schneider-hohendorf T, Pignolet B, et al. PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler. 2015 Oct 2. pii:1352458515607651. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Basnyat P, Hagman S, Kolasa M, et al. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients. Mult Scler Relat Disord. 2015;4:334–338.
   PubMed Web of Science ®Google Scholar
• Lieberman LA, Zeng W, Singh C, et al. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Neurology. 2016;86:375–381.
   PubMed Web of Science ®Google Scholar
• Egli A, Infanti L, Dumoulin A, et al Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis. 2009;199:836–846.
   Web of Science ®Google Scholar
• Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011;70:742–750.
   PubMed Web of Science ®Google Scholar
• Olsson T, Achiron A, Alfredsson L, et al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler. 2013;19:1533–1538.
   PubMed Web of Science ®Google Scholar
• Bhan V, Lapierre Y, Freeman MS, et al. Anti-JC virus antibody prevalence in Canadian MS patients. Can J Neurol Sci. 2014;41:748–752.
   PubMed Web of Science ®Google Scholar
• Kolasa M, Hagman S, Verkkoniemi-Ahola A, et al. Anti-JC virus seroprevalence in a Finnish MS cohort. Acta Neurol Scand. 2015 Sep 8. doi:10.1111/ane.12475. [Epub ahead of print].
   PubMedGoogle Scholar
• Outteryck O, Ongagna JC, Duhamel A, et al. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. J Neurol. 2012;259:2293–2298.
   PubMed Web of Science ®Google Scholar
• Outteryck O, Zéphir H, Salleron J, et al. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler. 2013 Sep 26. [Epub ahead of print].
   Google Scholar
• Raffel J. Poster 617. Barcelona: ECTRIMS; 2015.
   Google Scholar
• Schneider-Hohendorf T. Poster 622. Barcelona: ECTRIMS; 2015.
   Google Scholar
• Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med. 2009;361:1067–1074.
   PubMed Web of Science ®Google Scholar
• Chalkias S, Dang X, Bord E, et al. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol. 2014;75:925–934.
   PubMed Web of Science ®Google Scholar
• Pavlovic D, Patera AC, Nyberg F, et al. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015;8:255–273.
   PubMed Web of Science ®Google Scholar
• Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance natalizumab clearance and restoring leukocyte function. Neurology. 2009;72:402–409.
   PubMed Web of Science ®Google Scholar
• Tan K, Roda R, Ostrow R, et al. PML-IRIS in patients with HIV infection. Neurology. 2009;72:1458–1464.
   PubMed Web of Science ®Google Scholar
• Clifford DB. Neurological immune reconstitution inflammatory response: riding the tide of immune recovery. Curr Opin Neurol. 2015;28:295–301.
   PubMed Web of Science ®Google Scholar
• Antoniol C, Jilek S, Schluep M, et al. Impairment of JCV-specific T-cell responses by corticotherapy: effect on PML-IRIS management? Neurology. 2012;79:2258–2264.
   PubMed Web of Science ®Google Scholar
• Giacomini PS, Rozenberg A, Metz I, et al. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med. 2014;370:486–488.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Silva-Sanchez FA, Luna-Rivero C, et al. Maraviroc failed to control progressive multifocal leukoencephalopathy-associated IRIS in a patient with advanced HIV infection. Case Rep Med. 2014. doi:10.1155/2014/381480.
   PubMedGoogle Scholar
• Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004;306:1380–1383.
   PubMed Web of Science ®Google Scholar
• Verma S, Cikurel K, Koralnik IJ, et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis. 2007;196:709–711.
   PubMed Web of Science ®Google Scholar
• Clifford DB, Nath A, Cinque P, et al. A study of mefloquine treatment for progressive mutlifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol. 2013;19:351–358.
   PubMed Web of Science ®Google Scholar
• Schweikert A, Kremer M, Ringel F, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol. 2009;66:403–406.
   PubMed Web of Science ®Google Scholar
• Bozic C, LaGuette J, Panzara MA, et al. Natalizumab and central nervous system lymphoma: no clear association. Ann Neurol. 2009;66:261–262.
   PubMed Web of Science ®Google Scholar
• Phan-Ba R, Bisig B, Deprez M, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol. 2011;69:1060–1061.
   PubMed Web of Science ®Google Scholar
• Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med. 2008;358:647–648.
   PubMed Web of Science ®Google Scholar
• Ismail A, Kemp J, Sharrack B, et al. Melanoma complicating treatment with natalizumab (Tysabri) for multiple sclerosis. J Neurol. 2009;256:1771–1772.
   PubMed Web of Science ®Google Scholar
• Bergamaschi R, Montomoli C. Melanoma in multiple sclerosis treated with natalizumab: causal association and coincidence ? Mult Scler. 2009;15:1532–1533.
   PubMed Web of Science ®Google Scholar
• Vavricka BM, Baumberger P, Russmann S, et al. Diagnosis of melanoma under concomitant natalizumab therapy. Mult Scler. 2011;17:255–256.
   PubMed Web of Science ®Google Scholar
• Castela E, Lebrun-Frenay C, Laffon M, et al. Evolution of nevi during treatment with natalizumab: a prospective follow-up of patients treated with natalizumab. Arch Dermatol. 2011;147:72–76.
   PubMedGoogle Scholar
• Pharaon M, Tichet M, Lebrun-Frenay C, et al. Risk of naevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays. JAMA Dermatol. 2014;150:901–903.
   PubMed Web of Science ®Google Scholar
• Panzara MA, Bozic C, Sandrock AW. More on melanoma with transdifferentiation. N Engl J Med. 2008;359:99.
   PubMed Web of Science ®Google Scholar
• Outteryck O. P06.142. Seattle: AAN; 2009.
   Google Scholar
• Stosic M, De Jesus P, McCarthy J, et al. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology. 2011;77:505–507.
   PubMed Web of Science ®Google Scholar
• Midaglia L, Rodriguez Ruiz M, Munoz-Garcia D. Severe haematological complication during treatment with natalizumab. Mult Scler. 2012;18:1644–1646.
   PubMed Web of Science ®Google Scholar
• Cachia D, Izzy S, Berriosmorales I, et al. Drug-induced thrombocytopenia secondary to natalizumab treatment. BMJ Case Rep. 2014;30:piii: bcr2013203313.
   Google Scholar
• Wehner NG, Shopp G, Osterburg I, et al. Postnatal development in cynomolgus monkeys following prenatl exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009;86:117–130.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, Comi G, et al. Switching from natalizumab to fingolimod: a randomized placebo controlled study in RRMS. Neurology. 2015;262:1909–1917.
   Web of Science ®Google Scholar
• Cohen M, Maillart E, Tourbah A, et al. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol. 2014;71:436–441.
   PubMed Web of Science ®Google Scholar
• Jokubaitis VG, Li V, Kalincik T, et al. Fingolimod after natalizumab and the risk of short term relapse. Neurology. 2014;82:1204–1211.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Cree BA, de Sèze J, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 2015;82:1491–1498.
   Web of Science ®Google Scholar
• Laffaldano P, Ruggieri M, Viterbo RG, et al. Fingolimod versus interferon/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain. 2015;138:3275–3286.
   PubMed Web of Science ®Google Scholar
• Hadhoum N. Poster P615. Barcelona: ECTRIMS; 2015.
   Google Scholar
• Alvarez E. Poster P3.288. Washington: AAN; 2015.
   Google Scholar
• Lo Re M, Capobianco M, Ragonese P, et al. Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers. Neurol Ther. 2015;4:147–157.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–179.
   PubMed Web of Science ®Google Scholar
• Wingerchuck DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805–815.
   PubMed Web of Science ®Google Scholar
• Zéphir H, Bernard-Valnet R, Lebrun C, et al. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol. 2015;262:2329–2335.
   PubMed Web of Science ®Google Scholar
• Barnett MH, Prineas JW, Buckland ME, et al. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler. 2012;18:108–112.
   PubMed Web of Science ®Google Scholar
• Jacob A, Hutchinson M, Elsone L, et al. Does natalizumab therapy worsen neuromyelitis optica ? Neurology. 2012;79:1065–1066.
   PubMed Web of Science ®Google Scholar
• Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69:239–245.
   PubMedGoogle Scholar
• Jurynczyk M, Zaleski K, Selmaj K. Natalizumab and the development of extensive brain lesions in neuromyelitis optica. J Neurol. 2013;260:1919–1921.
   PubMed Web of Science ®Google Scholar
• Kitley J, Evangelou N, Küker W, et al. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. J Neurol Sci. 2014;339:223–225.
   PubMed Web of Science ®Google Scholar
• Govindarajan R, Salgado E. Is it too early to predict the failure of natalizumab in NMO? Arch Neurol. 2012;69:1085.
   PubMedGoogle Scholar
• Krumbholz M, Meinl E, Kumpfel T, et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008;71:1350–1354.
   PubMed Web of Science ®Google Scholar
• Garcia-Carrasco M, Mendoza-Pinto C, Cervera R. Diagnosis and classification of SUSAC syndrome. Autoimmun Rev. 2014;13:347–350.
   PubMed Web of Science ®Google Scholar
• Ryerson Z, Kister I, Snuderl M, et al. Incomplete Susac syndrome exacerbated after natalizumab. Neurol Neuroimmunol Neuroinflamm. 2015;2:e151.
   PubMedGoogle Scholar
• Mathey EK, Park SB, Hughes RA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86:973–985.
   PubMed Web of Science ®Google Scholar
• Wolf C, Menge T, Stenner MP, et al. Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Arch Neurol. 2010;67:881–883.
   PubMedGoogle Scholar
• Vallat JM, Mathis S, Ghorab K, et al. Natalizumab as a disease-modifying therapy in chronic inflammatory demyelinating polyneuropathy. Eur Neurol. 2015;73:294–302.
   PubMed Web of Science ®Google Scholar